{"success":true,"data":{"pressRelease":{"id":"68824","rtpr_id":"nACSyL166a","ticker":"WGS","exchange":"NASDAQ","all_tickers":["WGS"],"title":"GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC","author":"ACCESSWIRE","published_at":"2026-06-19T17:50:00.536Z","article_body":"NEW YORK, NY AND NEW ORLEANS, LA / ACCESS Newswire\n(https://www.accessnewswire.com/) / June 19, 2026 / Kahn Swick & Foti\n(https://pr.report/mr5l), LLC (\"KSF\") and KSF partner, former Attorney General\nof Louisiana, Charles C. Foti, Jr., remind investors with substantial losses\nthat they have until August 3, 2026 to file lead plaintiff applications in a\nsecurities class action lawsuit against GeneDx Holdings Corp.\n(https://pr.report/mr5m) (NASDAQ:WGS) (\"GeneDx\" or the \"Company\"), if they\npurchased or otherwise acquired the Company's shares between April 16, 2025\nand May 4, 2026, inclusive (the \"Class Period\"). This action is pending in the\nUnited States District Court for the District of Connecticut.\n\nWhat You May Do\n\nIf you purchased shares of GeneDx as above and would like to discuss your\nlegal rights and how this case might affect you and your right to recover for\nyour economic loss, you may, without obligation or cost to you, contact KSF\nManaging Partner Lewis Kahn toll-free at 1-877-515-1850 or via email\n(lewis.kahn@ksfcounsel.com), or visit\nhttps://www.ksfcounsel.com/cases/nasdaqgs-wgs/?prs=aw to learn more. If you\nwish to serve as a lead plaintiff in this class action, you must petition the\nCourt by August 3, 2026.\n\n>>>CLICK HERE (https://pr.report/mr5o) for more information\n\nAbout the Lawsuit\n\nGeneDx and certain of its executives are charged with failing to disclose\nmaterial information during the Class Period, violating federal securities\nlaws.\n\nOn May 4, 2026, the Company reported its financial results for the first\nquarter of fiscal year 2026, disclosing a drop in adjusted gross margin from\n74% to 69%, that it had missed its revenue estimates for both its exome and\ngenome lines, and lowered its guidance for full year revenue to $475 - $490\nmillion, down from $540 - $550 million. The Company also disclosed a $31.2\nmillion impairment loss attributable to its prior acquisition of Fabric\nGenomics, an AI-driven genomic interpretation company, which the Company had\ntouted as expected to expand its addressable market through multiple scalable\nrevenue streams and transform static data into a recurring revenue-generating\nplatform.\n\nOn this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.\n\nThe case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.\n\n>>>To Learn More, Click HERE (https://pr.report/mr5p)\n\nAbout Kahn Swick & Foti (https://pr.report/mr5q), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\n>>>For More Information about the case, Click HERE (https://pr.report/mr5s)\n\nContact:\n\n(https://app.accessnewswire.com/imagelibrary/48cb9385-2f1a-4d2d-a983-1bab629bb40c/image.png)\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook (https://pr.report/mr50) || Instagram\n(https://pr.report/mr51) || YouTube (https://pr.report/mr52) || TikTok\n(https://pr.report/mr53) || LinkedIn (https://pr.report/mr54)\n\nSOURCE: Kahn Swick & Foti, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/genedx-holdings-securities-fraud-class-action-result-of-acquisit-1179493)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSyL166a","title":"GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC","author":"ACCESSWIRE","ticker":"WGS","created":"2026-06-19T17:50:00.536Z","tickers":["WGS"],"exchange":"NASDAQ","article_body":"NEW YORK, NY AND NEW ORLEANS, LA / ACCESS Newswire\n(https://www.accessnewswire.com/) / June 19, 2026 / Kahn Swick & Foti\n(https://pr.report/mr5l), LLC (\"KSF\") and KSF partner, former Attorney General\nof Louisiana, Charles C. Foti, Jr., remind investors with substantial losses\nthat they have until August 3, 2026 to file lead plaintiff applications in a\nsecurities class action lawsuit against GeneDx Holdings Corp.\n(https://pr.report/mr5m) (NASDAQ:WGS) (\"GeneDx\" or the \"Company\"), if they\npurchased or otherwise acquired the Company's shares between April 16, 2025\nand May 4, 2026, inclusive (the \"Class Period\"). This action is pending in the\nUnited States District Court for the District of Connecticut.\n\nWhat You May Do\n\nIf you purchased shares of GeneDx as above and would like to discuss your\nlegal rights and how this case might affect you and your right to recover for\nyour economic loss, you may, without obligation or cost to you, contact KSF\nManaging Partner Lewis Kahn toll-free at 1-877-515-1850 or via email\n(lewis.kahn@ksfcounsel.com), or visit\nhttps://www.ksfcounsel.com/cases/nasdaqgs-wgs/?prs=aw to learn more. If you\nwish to serve as a lead plaintiff in this class action, you must petition the\nCourt by August 3, 2026.\n\n>>>CLICK HERE (https://pr.report/mr5o) for more information\n\nAbout the Lawsuit\n\nGeneDx and certain of its executives are charged with failing to disclose\nmaterial information during the Class Period, violating federal securities\nlaws.\n\nOn May 4, 2026, the Company reported its financial results for the first\nquarter of fiscal year 2026, disclosing a drop in adjusted gross margin from\n74% to 69%, that it had missed its revenue estimates for both its exome and\ngenome lines, and lowered its guidance for full year revenue to $475 - $490\nmillion, down from $540 - $550 million. The Company also disclosed a $31.2\nmillion impairment loss attributable to its prior acquisition of Fabric\nGenomics, an AI-driven genomic interpretation company, which the Company had\ntouted as expected to expand its addressable market through multiple scalable\nrevenue streams and transform static data into a recurring revenue-generating\nplatform.\n\nOn this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.\n\nThe case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.\n\n>>>To Learn More, Click HERE (https://pr.report/mr5p)\n\nAbout Kahn Swick & Foti (https://pr.report/mr5q), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\n>>>For More Information about the case, Click HERE (https://pr.report/mr5s)\n\nContact:\n\n(https://app.accessnewswire.com/imagelibrary/48cb9385-2f1a-4d2d-a983-1bab629bb40c/image.png)\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook (https://pr.report/mr50) || Instagram\n(https://pr.report/mr51) || YouTube (https://pr.report/mr52) || TikTok\n(https://pr.report/mr53) || LinkedIn (https://pr.report/mr54)\n\nSOURCE: Kahn Swick & Foti, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/genedx-holdings-securities-fraud-class-action-result-of-acquisit-1179493)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-19T17:50:00.579185667Z","server_sent_at_ms":1781891400579},"received_at":"2026-06-19T17:50:00.631Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/genedx-holdings-securities-fraud-class-action-result-of-acquisit-1179493"},"analysis":{"id":"58238","press_release_id":"68824","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Kahn Swick & Foti, LLC issued a shareholder solicitation notice regarding a securities class action lawsuit against GeneDx Holdings Corp (WGS).\n\nThe firm reminds investors who purchased shares between April 16, 2025, and May 4, 2026, that the deadline to file lead plaintiff applications is August 3, 2026.\n\nThe release cites the company's Q1 fiscal 2026 results, including a 49% stock drop, a $31.2 million impairment loss on its Fabric Genomics acquisition, and lowered revenue guidance, as the basis for the alleged misrepresentations.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"guidance_prior":"$540 - $550 million","impairment_loss":"$31.2 million","gross_margin_drop":"74% to 69%","stock_decline_pct":"49.2%","stock_decline_usd":"$33.42","guidance_lowered_to":"$475 - $490 million"}},"quotedText":"remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications","namedEntities":{"people":[{"name":"Lewis Kahn","role":"Managing Partner, Kahn Swick & Foti"},{"name":"Charles C. Foti, Jr.","role":"Partner, Kahn Swick & Foti; former Attorney General of Louisiana"}],"products":[],"companies":[{"name":"GeneDx Holdings Corp","ticker":"WGS","relationship":"defendant"},{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Fabric Genomics","relationship":"acquired subsidiary"}],"dollarAmounts":[{"amount":"$31.2 million","context":"impairment loss attributable to Fabric Genomics acquisition"},{"amount":"$475 - $490 million","context":"lowered full year revenue guidance"},{"amount":"$540 - $550 million","context":"prior full year revenue guidance"},{"amount":"$33.42","context":"per-share stock price decline"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by Kahn Swick & Foti, LLC. It contains standard lead-plaintiff deadline language and contact information for investors to discuss their rights. No new disclosure from the issuer, no certified class, and no settlement announced."},"tickerRelevance":{"others":[],"primary":"WGS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"signalType":"noise","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kahn Swick & Foti, LLC issued a shareholder solicitation notice regarding a securities class action lawsuit against GeneDx Holdings Corp (WGS).\n\nThe firm reminds investors who purchased shares between April 16, 2025, and May 4, 2026, that the deadline to file lead plaintiff applications is August 3, 2026.\n\nThe release cites the company's Q1 fiscal 2026 results, including a 49% stock drop, a $31.2 million impairment loss on its Fabric Genomics acquisition, and lowered revenue guidance, as the basis for the alleged misrepresentations.","key_figures":{"customDimensions":{"guidance_prior":"$540 - $550 million","impairment_loss":"$31.2 million","gross_margin_drop":"74% to 69%","stock_decline_pct":"49.2%","stock_decline_usd":"$33.42","guidance_lowered_to":"$475 - $490 million"}},"named_entities":{"people":[{"name":"Lewis Kahn","role":"Managing Partner, Kahn Swick & Foti"},{"name":"Charles C. Foti, Jr.","role":"Partner, Kahn Swick & Foti; former Attorney General of Louisiana"}],"products":[],"companies":[{"name":"GeneDx Holdings Corp","ticker":"WGS","relationship":"defendant"},{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Fabric Genomics","relationship":"acquired subsidiary"}],"dollarAmounts":[{"amount":"$31.2 million","context":"impairment loss attributable to Fabric Genomics acquisition"},{"amount":"$475 - $490 million","context":"lowered full year revenue guidance"},{"amount":"$540 - $550 million","context":"prior full year revenue guidance"},{"amount":"$33.42","context":"per-share stock price decline"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-19T17:50:18.312Z","global_importance":15,"audience_relevance":10,"importance_components":{"signalType":"noise","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":17668,"modelName":"george-droid-qwen-72b"}}